pentobarbital will decrease the level or effect of atogepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Closely. Suggested atogepant dosage with concomitant usage of strong or moderate CYP3A4 inducers is thirty mg or sixty mg qDay.Contraindicated (one)pentobarbital will lower the extent or outcome of cariprazine